Seres Therapeutics reports SER-155 achieved the primary endpoint with an 80% immunosuppressive-free response by Day 15 and 33% complete remission. Biomarker data showed reductions in fecal calprotectin and albumin by Day 43, supporting continued development. Despite positive data, MCRB shares declined about 11% on the news, indicating a cautious near-term reception while longer-term durability and safety readouts remain key catalysts.
Seres Therapeutics (MCRB) has announced a strategic shift in operations, resulting in a decline in shares during Thursday's premarket trading. This strategic realignment could impact investor sentiment and future business performance, highlighting the importance of closely monitoring subsequent developments.
